aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

ATYR Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

aTyr Pharma, Inc.NASDAQ: ATYR

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin not reported for Q1 FY2026

Over 3 fiscal years it narrowed by 38572.9 pp.

Context

  • Net margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 6 analysts of -1062.1% for the fiscal year ending Dec 2026, up from -39009.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-39009.5%-11765.6 pp YoY
LTMMar 2026
-36857.4%— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-11765.6 pp+37947.4 pp+49713.0 pp
3 years-38572.9 pp+38065.8 pp+76638.8 pp
5 years+39024.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-39009.5%
Year-over-year change
-11765.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ATYR compares with its peers on the latest reported figures

  • ATYR's LTM Mar 2026 net margin of -36857.4% is the lowest of the 4 companies compared; the peer median is -98.7%.
  • Over three fiscal years its change of -38572.9 pp compares with a peer median of +135.9 pp.
ATYR Competitors Peer median
Net Margin for ATYR and competitors
Company Period LTM level YoY 3-year change
HYFTMindWalk Holdings Corp.LTM Jan 2026-66.4% +193.3 pp-37.0 pp
DTILPrecision BioSciences, Inc.LTM Mar 2026-98.7% -55.7 pp+308.8 pp
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026-2193.7% +1234.9 pp—
ATYRaTyr Pharma, Inc.LTM Mar 2026-36857.4% —-38572.9 pp
RLMDRelmada Therapeutics, Inc.FY2025— ——
ALXOALX Oncology Holdings Inc.FY2025— ——
UNCYUnicycive Therapeutics, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding ATYR) -98.7%+193.3 pp+135.9 pp

Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue010.39M353K235K190K
Cost of Revenue1.3M1.7M001.55M
Gross Profit(1.3M)8.69M353K235K(1.36M)
Gross Margin—83.7%100.0%100.0%-717.4%
Research & Development23.26M42.81M42.29M54.37M60.22M
Selling, General & Admin10.75M12.29M12.98M13.78M17.6M
Operating Expenses32.71M55.1M55.27M68.15M76.26M
Depreciation & Amortization1.3M1.7M2.74M1.54M1.55M
EBITDA(32.47M)(43.65M)(47.66M)(62.48M)(72.57M)
EBITDA Margin—-420.3%-13500.3%-26588.1%-38192.1%
Operating Income(34.02M)(46.4M)(54.92M)(67.91M)(77.63M)
Operating Margin—-446.8%-15557.8%-28899.6%-40856.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses238K1.06M4.52M3.89M3.51M
Income Before Tax(33.78M)(45.34M)(50.4M)(64.02M)(74.12M)
Pre-Tax Margin—-436.6%-14276.8%-27243.4%-39009.5%
Income Tax Expense00000
Net Income(33.77M)(45.34M)(50.39M)(64.02M)(74.12M)
Net Margin—-436.5%-14274.5%-27243.8%-39009.5%
EPS (Basic)(1.77)(1.60)(0.94)(0.86)(0.80)
EPS (Diluted)(1.77)(1.60)(0.94)(0.86)(0.80)
Weighted Avg Shares19.08M28.42M53.61M74.26M92.99M
Weighted Avg Shares (Diluted)19.08M28.42M53.61M74.26M92.99M

aTyr Pharma, Inc.

NASDAQ:ATYR

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.